Asset Allocation

As of November 30, 2025.
Type % Net
Cash 4.21%
Stock 45.88%
Bond 50.20%
Convertible 0.00%
Preferred 0.00%
Other -0.29%
View Asset Allocation
Start Trial

Market Capitalization

As of November 30, 2025
Large 91.07%
Mid 8.87%
Small 0.06%
View Market Capitalization
Start Trial

Region Exposure

% Developed Markets: 93.62%    % Emerging Markets: 1.04%    % Unidentified Markets: 5.34%

Americas 89.36%
87.73%
Canada 0.83%
United States 86.90%
1.63%
Chile 0.44%
Mexico 0.36%
As of November 30, 2025. Region breakdown data is calculated by using the long position holdings of the portfolio.
Greater Europe 5.14%
United Kingdom 0.57%
4.33%
France 0.71%
Germany 0.61%
Ireland 1.80%
Italy 0.17%
Netherlands 0.20%
Norway 0.21%
Spain 0.13%
Switzerland 0.25%
0.00%
0.24%
Greater Asia 0.16%
Japan 0.16%
0.00%
0.00%
0.00%
Unidentified Region 5.34%

Bond Credit Quality Exposure

AAA 6.29%
AA 32.16%
A 2.50%
BBB 31.09%
BB 9.11%
B 0.00%
Below B 0.00%
    CCC 0.00%
    CC 0.00%
    C 0.00%
    DDD 0.00%
    DD 0.00%
    D 0.00%
Not Rated 0.00%
Not Available 18.85%
Short Term 0.00%
As of November 30, 2025
View Bond Credit Quality Exposure
Start Trial

Stock Sector Exposure

Cyclical
22.18%
Materials
0.00%
Consumer Discretionary
5.57%
Financials
14.32%
Real Estate
2.29%
Sensitive
57.18%
Communication Services
11.36%
Energy
5.19%
Industrials
8.97%
Information Technology
31.66%
Defensive
20.65%
Consumer Staples
4.12%
Health Care
13.02%
Utilities
3.51%
Not Classified
0.00%
Non Classified Equity
0.00%
Not Classified - Non Equity
0.00%
As of November 30, 2025
View Region Exposure
Start Trial

Bond Sector Exposure

As of November 30, 2025
Type % Net
Government 27.61%
Corporate 36.59%
Securitized 33.14%
Municipal 0.00%
Other 2.66%
View Bond Sector Exposure
Start Trial

Bond Maturity Exposure

Short Term
0.00%
Less than 1 Year
0.00%
Intermediate
35.66%
1 to 3 Years
4.37%
3 to 5 Years
16.02%
5 to 10 Years
15.27%
Long Term
60.16%
10 to 20 Years
11.78%
20 to 30 Years
38.93%
Over 30 Years
9.45%
Other
4.18%
As of November 30, 2025
View Bond Maturity Exposure
Start Trial